{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:29:36Z","timestamp":1790882976702,"version":"4.1.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Immunotherapy efficacy in gastric cancer (GC) is often constrained by the tumor microenvironment (TME), which is profoundly influenced by aberrant metabolism. Asparagine, an amino acid critical for neoplastic proliferation, also modulates CD8+ T cell metabolic programming. We investigated the impact of targeting asparagine on the GC immune microenvironment and its potential to synergize with anti-PD-L1 therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The therapeutic efficacy of asparagine targeting was evaluated in GC tumor models. CD8+ T cell populations within the TME were analyzed by flow cytometry, while cytokine and chemokine levels (IFN-\u03b3, GZMB, CXCL9, CXCL10) were quantified by ELISA. The effects on CD8+ T cell activation and antitumor function were assessed in vitro and in vivo. Synergistic efficacy with anti-PD-L1 therapy was evaluated in GC models, and the dependency on CD8+ T cells was confirmed via antibody-mediated depletion experiments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Targeting asparagine inhibited GC growth in vitro and in vivo, implicating immune system involvement. Mechanistically, asparagine targeting significantly increased the proportion of CD8+ T cells within the TME and upregulated the expression of IFN-\u03b3, GZMB, CXCL9, and CXCL10. Furthermore, combining asparagine targeting with anti-PD-L1 therapy produced synergistic antitumor activity. This combined therapeutic effect was significantly attenuated by the depletion of CD8+ T cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our findings indicate that targeting asparagine promotes CD8+ T cell activation and infiltration, thereby remodeling the GC immune microenvironment to enhance host antitumor immunity. The combination of asparagine targeting with anti-PD-L1 therapy elicits potent, synergistic antitumor effects that are demonstrably dependent on CD8+ T cells. This study provides a strong rationale for targeting asparagine metabolism as a novel strategy to improve immunotherapeutic outcomes in GC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1626581","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:24:06Z","timestamp":1761647046000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Targeting asparagine potentiates anti-PD-L1 immunotherapy in gastric cancer by enhancing CD8+ T cell anti-tumor response"],"prefix":"10.3389","volume":"16","author":[{"given":"Mingpai","family":"Ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enyuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xusheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaorui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21114012","article-title":"Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies","volume":"21","author":"Machlowska","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41568-023-00560-y","article-title":"Dynamics and specificities of T cells in cancer immunotherapy","volume":"23","author":"Oliveira","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i8.2403","article-title":"Advanced gastric cancer: Current treatment landscape and future perspectives","volume":"22","author":"Digklia","year":"2016","journal-title":"World J Gastroenterol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/bfgp\/ely019","article-title":"Immunotherapy for gastric cancer: dilemmas and prospect","volume":"18","author":"Zhao","year":"2019","journal-title":"Brief Funct Genomics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11864-020-00774-4","article-title":"Targeted therapies in advanced gastric cancer","volume":"21","author":"Patel","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.07.045","article-title":"Burden of gastric cancer","volume":"18","author":"Thrift","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1016\/j.cell.2024.03.011","article-title":"Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8+ T cells","volume":"187","author":"Cao","year":"2024","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242417422","article-title":"The role of tumor metabolic reprogramming in tumor immunity","volume":"24","author":"Zhang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.7150\/thno.82920","article-title":"The role of lipid metabolic reprogramming in tumor microenvironment","volume":"13","author":"Yang","year":"2023","journal-title":"Theranostics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01316-8","article-title":"The cancer metabolic reprogramming and immune response","volume":"20","author":"Xia","year":"2021","journal-title":"Mol Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-024-01304-w","article-title":"Targeting metabolism to enhance immunotherapy within tumor microenvironment","volume":"45","author":"Liang","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00339-6","article-title":"Targeting cancer metabolism in the era of precision oncology","volume":"21","author":"Stine","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06061-0","article-title":"Lysine catabolism reprograms tumour immunity through histone crotonylation","volume":"617","author":"Yuan","year":"2023","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0620-5","article-title":"New aspects of amino acid metabolism in cancer","volume":"122","author":"Vettore","year":"2020","journal-title":"Br J Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2021.0461","article-title":"Cancer metabolism and dietary interventions","volume":"19","author":"Qian","year":"2021","journal-title":"Cancer Biol Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s12276-020-0375-3","article-title":"Amino acids in cancer","volume":"52","author":"Lieu","year":"2020","journal-title":"Exp Mol Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.09.005","article-title":"CD8+ T cells in the cancer-immunity cycle","volume":"56","author":"Giles","year":"2023","journal-title":"Immunity"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.715234","article-title":"CD8+ T cell exhaustion in cancer","volume":"12","author":"Dolina","year":"2021","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.216043","article-title":"CD8+ T cell exhaustion and cancer immunotherapy","volume":"559","author":"Wang","year":"2023","journal-title":"Cancer Lett"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2174\/1871520622666220106103336","article-title":"L-asparaginase-mediated therapy in L-asparagine auxotrophic cancers: A review","volume":"22","author":"Sindhu","year":"2022","journal-title":"Anticancer Agents Med Chem"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cis.2023.102915","article-title":"L-Asparaginase delivery systems targeted to minimize its side-effects","volume":"316","author":"Talluri","year":"2023","journal-title":"Adv Colloid Interface Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004041","article-title":"ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatment","volume":"5","author":"Chiu","year":"2021","journal-title":"Blood Adv"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12010-015-1917-3","article-title":"A comprehensive review on L-asparaginase and its applications","volume":"178","author":"Batool","year":"2016","journal-title":"Appl Biochem Biotechnol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.cmet.2020.03.008","article-title":"ZBTB1 regulates asparagine synthesis and leukemia cell response to L-asparaginase","volume":"31","author":"Williams","year":"2020","journal-title":"Cell Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112724","article-title":"The integrated stress response effector ATF4 is an obligatory metabolic activator of NRF2","volume":"42","author":"Kre\u00df","year":"2023","journal-title":"Cell Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.09.021","article-title":"ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation","volume":"22","author":"Qing","year":"2012","journal-title":"Cancer Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-024-03681-x","article-title":"ATF4 in cellular stress, ferroptosis, and cancer","volume":"98","author":"Tang","year":"2024","journal-title":"Arch Toxicol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-3561","article-title":"PTTG1 reprograms asparagine metabolism to promote hepatocellular carcinoma progression","volume":"83","author":"Zhou","year":"2023","journal-title":"Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cells11203273","article-title":"Targeting asparagine synthetase in tumorgenicity using patient-derived tumor-initiating cells","volume":"11","author":"Nishikawa","year":"2022","journal-title":"Cells"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00316.2024","article-title":"Asparagine as a signal for glutamine sufficiency via asparagine synthetase: a fresh evidence-based framework in physiology and oncology","volume":"327","author":"Olawuni","year":"2024","journal-title":"Am J Physiol Cell Physiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3522","article-title":"Amino acid signalling upstream of mTOR","volume":"14","author":"Jewell","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.115881","article-title":"Amino acid metabolism and autophagy in skeletal development and homeostasis","volume":"146","author":"Suzuki","year":"2021","journal-title":"Bone"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00099-20","article-title":"The molecular mechanisms regulating the KEAP1-NRF2 pathway","volume":"40","author":"Baird","year":"2020","journal-title":"Mol Cell Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00023.2017","article-title":"The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis","volume":"98","author":"Yamamoto","year":"2018","journal-title":"Physiol Rev"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9304383","article-title":"High level of uric acid promotes atherosclerosis by targeting NRF2-mediated autophagy dysfunction and ferroptosis","volume":"2022","author":"Yu","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-023-00856-1","article-title":"Asparagine restriction enhances CD8+ T cell metabolic fitness and antitumoral functionality through an NRF2-dependent stress response","volume":"5","author":"Gnanaprakasam","year":"2023","journal-title":"Nat Metab"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02378-8","article-title":"Tumor microenvironment, immune response and post-radiotherapy tumor clearance","volume":"22","author":"Koukourakis","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.01.043","article-title":"Tumor microenvironment and therapeutic response","volume":"387","author":"Wu","year":"2017","journal-title":"Cancer Lett"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1325360","article-title":"Tumor cell metabolic reprogramming and hypoxic immunosuppression: driving carcinogenesis to metastatic colonization","volume":"14","author":"Katopodi","year":"2023","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1626581\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:24:08Z","timestamp":1761647048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1626581\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":44,"alternative-id":["10.3389\/fimmu.2025.1626581"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1626581","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"article-number":"1626581"}}